CONDENSED BALANCE SHEETS

April 30, 2021 (Unaudited)

	April 30,	July 31,
ASSETS	2021	2020
CURRENT ASSETS
Cash	`$34`	`$1,343`
Prepaid expenses	`25,000`	`25,000`
Total Current Assets	`25,034`	`26,343`

Total Assets	`$25,034`	`$26,343`

IABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES
Accounts payable and accrued expenses	`$1,452,973`	`$1,349,444`
Convertible notes payable, net of discount and premiums	`1,673,268`	`1,924,153`
Settlement under3(a)(10), including premiums	`1,780,250`	`1,780,250`
Note derivative liability	`568,060`	`538,059`
Settlement reserves	`1,110,241`	`1,492,549`
Total Current Liabilities	`6,584,792`	`7,084,455`

Total Liabilities	`6,584,792`	`7,084,455`

STOCKHOLDERS' DEFICIT
Preferred stock; par value of $.001, 25,000,000 shares authorized;
1,000,000 and 1,000,000 shares issued and outstanding at
April 30, 2021 and July 31, 2020, respectively	`1,000`	`1,000`
Common stock; par value of $.001, 10,000,000,000 shares authorized;
4,516,264,729 and 4,117,033,449 shares issued and outstanding at
April 30, 2021 and July 31, 2020, respectively	`4,516,262`	`4,117,031`
Additional paid in capital	`972,072`	`1,196,495`
Accumulated deficit	`(12,049,092)`	`(12,372,638)`
Total Stockholders' Deficit	`(6,559,758)`	`(7,058,112)`

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	`$25,034`	`$26,343`

The accompanying notes are an integral part of these condensed financial statements.

CONDENSED STATEMENT OF OPERATIONS

FOR THE THREE AND NINE MONTHS ENDED APRIL 30, 2021 AND 2020

(Unaudited)

	For the Three Months Ended April 30,		For the Nine Months Ended April 30,
	2021	2020	2021	2020

REVENUES	`$-`	`$-`	`$-`	`$871`
COST OF SALES	`-`	`-`	`-`	`1,278`

GROSS PROFIT	`-`	`-`	`-`	`(407)`

OPERATING EXPENSES
General and administrative	`158`	`48,863`	`4,042`	`124,557`
Professional fees	`10,890`	`(17,350)`	`26,890`	`82,497`
Marketing and advertising	`-`	`4,500`	`-`	`14,439`
Salaries and wages	`60,000`	`32,765`	`180,000`	`111,315`

Total Operating Expenses	`71,048`	`68,778`	`210,932`	`332,808`

OPERATING (LOSS)	`(71,048)`	`(68,778)`	`(210,932)`	`(333,215)`

OTHER INCOME (EXPENSE)
Other income	`458,516`	`-`	`458,516`	`-`
Derivative expense	`-`	`(60,140)`	`(30,001)`	`(60,140)`
Gain on extinguishment of debt	`220,390`	`-`	`220,390`	`-`
Interest expense	`(33,713)`	`(52,635)`	`(114,427)`	`(259,827)`

Total Other Income (Expense)	`645,193`	`(112,775)`	`534,478`	`(319,967)`

NET INCOME (LOSS) BEFORE INCOME TAXES	`574,145`	`(181,553)`	`323,546`	`(653,182)`
Provision for income taxes	`-`	`-`	`-`	`-`

NET INCOME (LOSS)	`$574,145`	`$(181,553)`	`$323,546`	`$(653,182)`

BASIC AND DILUTED INCOME (LOSS) PER SHARE	`$0.0001`	`$(0.0001)`	`$0.0001`	`$(0.0002)`

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING

Weighted Average Shares Outstanding - Basic and Diluted	`4,126,004,938`	`3,371,922,134`	`4,119,958,220`	`2,855,830,897`

The accompanying notes are an integral part of these condensed financial statements.

NUTRANOMICS, INC.

CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT

FOR THE THREE AND NINE MONTHS ENDED APRIL 30, 2021 AND 2019

(Unaudited)

For the Three Months Ended April 30, 2021

	Preferred Stock					Common Stock										Total
	Shares		Amount			Shares		Amount		Additional Paid in Capital			Accumulated Deficit			Stockholders' (Deficit)
Balance, January 31, 2021		1,000,000		$	1,000		4,117,033,449	$	4,117,031	$	1,196,495		$	(12,623,237	)	$	(7,308,711	)

Common stock issued on conversion of convertible notes		-			-		399,231,280		399,231		(224,423	)		-			174,808

Net income for the three months ended April 30, 2021		-			-		-		-		-			574,145			574,145

Balance April 30, 2021		1,000,000		$	1,000		4,516,264,729	$	4,516,262	$	972,072		$	(12,049,092	)	$	(6,559,758	)

For the Three Months Ended April 30, 2020

	Preferred Stock					Common Stock										Total
	Shares		Amount			Shares		Amount		Additional Paid in Capital			Accumulated Deficit			Stockholders' (Deficit)
Balance, January 31, 2020		1,000,000		$	1,000		2,942,869,449	$	2,942,867	$	2,335,189		$	(11,893,472	)	$	(6,614,416	)

Common stock for conversion of convertible note principal		-			-		162,000,000		162,000		(126,531	)		-			35,469

Cancellation from conversion error		-			-		(27,300,000)		(27,300)		27,300			-			-

Common stock for settlement of 3(a)(10)		-			-		494,025,000		494,025		(494,025	)		-			-

Net loss for the three months ended April 30, 2020		-			-		-		-		-			(181,553	)		(181,553	)

Balance, April 30, 2020		1,000,000		$	1,000		3,571,594,449	$	3,571,592	$	1,741,933		$	(12,075,025	)	$	(6,760,500	)

NUTRANOMICS, INC.

CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT

FOR THE THREE AND NINE MONTHS ENDED APRIL 30,2021 AND 2019

(Unaudited)

For the Nine Months Ended April 30,2021

	Preferred Stock					Common Stock										Total
	Shares		Amount			Shares		Amount		Additional Paid in Capital			Accumulated Deficit			Stockholders' (Deficit)
Balance, July 31, 2020		1,000,000		$	1,000		4,117,033,449	$	4,117,031	$	1,196,495		$	(12,372,638	)	$	(7,058,112	)

Common stock for conversion of convertible note principal		-			-		162,000,000		162,000		(126,531	)		-			35,469

Net income for the nine months ended April 30, 2021		-			-		-		-		-			323,546			323,546

Balance April 30, 2021		1,000,000		$	1,000		4,516,264,729	$	4,516,262	$	972,072		$	(12,049,092	)	$	(6,559,758	)

For the Nine Months Ended April 30, 2020

	Preferred Stock					Common Stock										Total
	Shares		Amount			Shares		Amount		Additional Paid in Capital			Accumulated Deficit			Stockholders' (Deficit)
Balance, July 31, 2019		1,000,000		$	1,000		2,161,787,677	$	2,161,785	$	2,898,955		$	(11,421,843	)	$	(6,360,103	)

Common stock for conversion of convertible note principal		-			-		826,257,772		826,258		(573,473	)		-			252,785

Cancellation from conversion error		-			-		(27,300,000)		(27,300)		27,300			-			-

Common stock for settlement of 3(a)(10)		-			-		610,849,000		610,849		(610,849	)		-			-

Net loss for the nine months ended April 30, 2020		-			-		-		-		-			(653,182	)		(653,182	)

Balance, April 30, 2020		1,000,000		$	1,000		3,571,594,449	$	3,571,592	$	1,741,933		$	(12,075,025	)	$	(6,760,500	)

The accompanying notes are an integral part of these condensed financial statements.

NUTRANOMICS, INC.
CONDENSED STATEMENTS OF CASH FLOWS April 30, 2021 & 2020 (Unaudited)
	The Nine Months Ended: For the Nine Months Ended
	April 30,
	2021		2020
OPERATING ACTIVITIES
Net Income (Loss)	$	`323,546`	$	`(653,182)`
Adjustments to reconcile net (loss) to net cash used in operating activities:
Intangible asset impairment charge		`-`		`3,703`
Interest expense for note premium		`-`		`38,333`
Amortization of debt discount		`-`		`9,494`
Short-term notes issued for professional fees and expenses		`-`		`25,000`
Stock based expense		`3,390`		`3,300`
Derivative expense		`30,001`		`60,140`
Gain on extinguishment of debt		`(220,390)`		`-`
Changes in operating assets and liabilities:
Other current assets		`-`		`(200,000)`
Accounts payable and accrued expenses		`243,152`		`136,787`

Net Cash (Used in) Operating Activities		`(2,609)`		`(576,425)`

FINANCING ACTIVITIES
Proceeds from convertible notes				`20,000`
Proceeds from profit share partner		`-`		`550,874`
Proceeds form officer loans		`1,300`		`7,610`
Net Cash Provided by Financing Activities		`1,300`		`578,484`

Net (Decrease) Increase in Cash		`(1,309)`		`2,059`

Cash, Beginning of Period		`1,343`		`739`

Cash, End of Period	$	`34`	$	`2,798`

Supplemental Disclosures of Cash Flow Information:
Cash paid during the period for:
Interest	$	`-`	$	`-`

Non-cash Investing and Financing activities:		`-`
Common stock for conversion of convertible note principal	$	`171,418`	$	`253,785`
Reclassification of note to convertible note due to assignment	$	`10,000`	$	`-`

The accompanying notes are an integral part of these condensed financial statements.

NUTRANOMICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

April 30, 2021 (Unaudited)

NOTE 1- NATURE OF OPERATIONS

Corporate History

Health Education Corporation d/b/a NutraNomics, (the "Company or Nutranomics") was incorporated under the laws of the State of Delaware on February 14, 1996. The Company was originally organized to provide education services, books, cassette tapes and public presentations. The Company utilized several revenue generating tools in order to accomplish this goal including Live Blood Analysis, iridology, bone density screening and other self-help methods. In 1998, the Company changed its incorporation to the State of Utah. In 2001, the Company created its own line of nutritional products that quickly became its leading revenue source. The Company filed for the d/b/a. of “NutraNomics” in order to fully prepare and utilize the brand name for expansion. In retail outlets and to its clientele, the Company is now known as Nutranomics. The Company sells co-branded supplements direct to the public, through marketing partners and to third party health practitioners. The Company maintains multiple trademarks, trade names and patents.

Merger

On September 13, 2013, Buka Ventures, Inc. ("Buka"), a Nevada corporation since March 15, 2007 and the Company, executed and delivered a Share Exchange Agreement (the "Share Agreement") and all required or necessary documentation to complete a merger (collectively, the "Transaction Documents"), whereby Buka became the parent company and Nutranomics became the wholly-owned subsidiary on the closing of the Share Agreement. Prior to the closing of this transaction and pursuant to the Share Exchange Agreement, Buka canceled 25,000,000 of its 46,500,000 issued and outstanding common shares and simultaneously issued 25,005,544 shares of its common stock in exchange for 8,994,800 shares of Nutranomics common stock. The merger was treated as a reverse acquisition and a recapitalization of a public company. Accordingly, the historic financial statements of the Company are the historic financial statements of Nutranomics. Buka’s name was formally changed to “Nutranomics, Inc.” in connection with the transaction. The “Company” hereinafter refers to Nutranomics, Inc., the Nevada parent corporation, or Health Education Corporation d/b/a Nutranomics, the Utah subsidiary corporation, as the context requires (Health Education Corporation d/b/a Nutranomics terminated its legal entity status in Utah on December 31, 2013).

Change of State of Incorporation

On September 9, 2019 the Company filed Articles of Continuance with the Secretary of State of Wyoming, which changed the corporate registration from Nevada to Wyoming in accordance with the resolution of the Company’s board of directors dated May 23, 2019.

Increase in Authorized Shares of Common Stock

On March 17, 2020, the Wyoming Secretary of State approved the Company’s increase of authorized common stock to 10,000,000,000.

NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for annual financial information and the rules and regulations of the Securities and Exchange Commission (“SEC”) for annual financial information. In the opinion of the Company’s management, the accompanying financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the year ending ended July 31, 2021.

NUTRANOMICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

April 30, 2021 (Unaudited)

Going Concern

The Company’s financial statements are prepared using generally accepted accounting principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. For the nine months ended April 30,2021 the Company has incurred net lincome of $323,546 and used cash of $2,609 in operations. Further, the Company has negative working capital of $6,559,758, a shareholders’ deficit of $6,559,758 and an accumulated deficit of $12,049,092 at April 30,2021 and does not have the requisite liquidity to pay its current obligations. Most of the debt obligations are currently in default. These factors, among others, raise substantial doubt about its ability to continue as a going concern. Management will seek to increase revenues and reduce costs, while raising capital through the sale of its stock. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the economic environment, which management believes to be reasonable under the circumstances. Management adjusts such estimates and assumptions when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from those estimates.

Derivative Liabilities

In connection with the private placement of certain convertible notes beginning in January 2014, the Company became contingently obligated to issue shares of common stock in lieu of cash to liquidate the notes. The Company values these convertible notes payable using the multinomial lattice method that values the derivative liability within the notes based on a probability weighted discounted cash flow model. The resulting liability is valued at each reporting date and the change in the liability is reflected as change in derivative liability in the statement of operations.

Convertible Notes with Fixed Rate Conversion Options

The Company may enter into convertible notes, some of which contain, predominantly, fixed rate conversion features, whereby the outstanding principal and accrued interest may be converted by the holder, into common shares at a fixed discount to the market price of the common stock at the time of conversion. This results in a fair value of the convertible note being equal to a fixed monetary amount. The Company records the convertible note liability at its fixed monetary amount by measuring and recording a premium, as applicable, on the Note date with a charge to interest expense in accordance with ASC 480 - “Distinguishing Liabilities from Equity”.

Revenue Recognition

Our revenue is derived from wholesale bulk products and retail products sold to individuals and resellers.

Effective October 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) 606, Revenue From Contracts With Customers, which is effective for public business entities with annual reporting periods beginning after December 15, 2017. This new revenue recognition standard (new guidance) has a five-step process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; and e) Recognize revenue when (or as) performance obligations are satisfied. The impact of the Company’s initial application of ASC 606 did not have a material impact on its financial statements and disclosures and there was no cumulative effect of the adoption of ASC 606. The Company defers recognition of revenue until the performance obligations are fulfilled. Fulfillment is triggered by shipment of the related product to the contracted customer. Allowances for returns and retail incentives are deducted from the revenue to be recognized.

NUTRANOMICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

April 30, 2021 (Unaudited)

The Company also recognizes revenues from the distribution of its product through trade partners. Related revenues consist of product costs, distribution fees, testing and labeling costs, as well as any associated administrative fees. The Company recognizes these revenues after the product has been shipped from the outsource manufacturer to the trade partner. The Company has contractual obligation to pay the outsource manufacturers, and as a principal in these arrangements the Company includes the total product price as revenue in accordance with applicable accounting guidance. The Company has separately negotiated contractual relationships with its trade partners, and under contracts with these trade partners the Company assumes the credit risk of product produced by the outsource manufacturer and dispensed to the trade partner.

Cost of Sales

The Company includes product costs (i.e. material, direct labor and overhead costs), shipping and handling expense, insurance on inventory, production-related depreciation expense and product license agreement expense in cost of sales.

Net Loss Per Share

Even though the Company has incurred income for the nine months ended April 30, 2021, this arises from one time write offs of liabilities; the Company will have a net loss for the year ended July 31, 2021 and with the net loss in 2020, the potentially dilutive shares are anti-dilutive and are thus not added into the loss per share calculations.

Basic loss per share is calculated by dividing the loss attributable to stockholders by the weighted-average number of shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings (loss) of the Company. Diluted loss per share is computed by dividing the loss available to stockholders by the weighted average number of shares outstanding for the period and dilutive potential shares outstanding unless such dilutive potential shares would result in anti-dilution. As of April 30, 2021, the outstanding principal balance of convertible notes, the settlement balance for the 3(a)(10), and accrued interest of the convertible notes, totaled $3,504,657 and was convertible into 4,163,335,831 shares of common stock. It should be noted that contractually the limitations on these notes and warrants limit the number of shares converted to 4.99% or 9.99% of the outstanding shares.

NOTE 3 – COMMIMENTS, CONTINGENCIES AND LEGAL MATTERS

The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or un-asserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or un-asserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.

Office Lease

The Company has a month-to-month lease for a sales and marketing office in Gladstone, Oregon. Since the lease term is monthly the Company has determined that the present value of the obligation is equal to the actual cash settlement no present value has been calculated. Additionally, no obligation and future service use assets have been recorded.

NUTRANOMICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

April 30, 2021 (Unaudited)

Litigation

On August 15, 2019, a default judgement was issued to Typenex Co-Investment, LLC, for $559,367, arising from the Company’s default on the December 2, 2014, Typenex convertible note. The Company has reclassified the convertible note principal and accrued interest balances, along with related derivative balances to settlement reserves. The court also awarded the former note holder legal fees and interest of 22% from the date of the judgement until settled. Management has engaged legal counsel on the matter and has proposed various settlements with Typenex and believes that a settlement will be reached during the next fiscal year end. Management will assess the settlement reserve for adequacy once legal fees and interest is specified by the plaintiff.

The plaintiff has filed a motion seeking a court hearing to determine the existence of any assets to satisfy the default judgement.

Inventory Purchase Commitment and Profit Sharing Arrangement

On September 19, 2019, the Company entered into an agreement to purchase 100,000 pounds of industrial hemp with a CBD content of 14% or greater and THC content of less than .03% with a commercial hemp farm in California. A purchase deposit of $200,000 was made on September 25, 2019. The full amount of the deposit was recognized as expense as of July 31, 2020.

On September 20, 2019, the Company entered into a financing and profit-sharing arrangement with a third party to provide the working capital needed to purchase the hemp described above, from a vendor selected by the profit sharing party. The arrangement provided $550,874 for the deposit above on the hemp purchase and financing for transportation and initial processing into CBD. Repayment of the initial funding and profit sharing was expected once the final processing into CBD was complete and the end product was paid for by the ultimate purchaser. During the year ended July31, 2020, the Company determined that the hemp vendor could not meet the delivery obligation under the terms of the agreement. As a result the Company is in the process of either obtaining the hemp or a CBD distillate to fulfill the terms of the agreement with the profit sharing party, which has been informed of the situation. The Company has discussed various alternatives with the third party to settle the matter; the profit sharing party recognizes that the terms of the agreement specify that repayment is predicated on finished product sales, however the potential for arbitration is not considered likely but possible and final result is uncertain. The Company has recognized the full amount of $550,874 as a liability recorded in settlement reserves, at April 30, 2021.

Other

The Company believes that it has taken into consideration all material, asserted claims and unasserted potential claims, in establishing settlement reserves, including current and legacy obligations under former management prior to July 2016.

Management of the Company has conducted a diligent search and concluded that, other than as disclosed herein, there were no commitments, contingencies, or legal matters pending at the balance sheet dates that have not been disclosed.

NOTE 4 – PREPAID EXPENSES OTHER CURRENT ASSETS

Prepaid expenses were recorded for services to be rendered in conjunction with management’s project to improve financial and operational structure; a note was issued and recorded as payment for these services.

		April 30,2021		July 31, 2020
Prepaid expenses		`$25,000`		`$25,000`

NUTRANOMICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

April 30, 2021 (Unaudited)

NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts Payable and Accrued Expenses at October and July31, 2020, represent the following:

	April 30,2021	July 31, 2020
Accounts payable	`$550,429`	`$550,729`
Accrued interest	`518,192`	`620,896`
Other accrued expenses	`384,352`	`177,819`
Total	`$1,452,973`	`$1,349,444`

NOTE 6 – CONVERTIBLE NOTES PAYABLE

Convertible notes payable consisted of the following:

	April 30, 2021	July 31, 2020
Principal – Convertible notes issued prior to July 2016	`$491,333`	`$592,218`
Principal – Convertible notes issued prior to July 2016 under settlement arrangements	`134,382`	`144,382`
Principal – Convertible notes issued since July 2016	`555,500`	`620,500`
Principal 3(a)(10) settlement arrangement	`890,125`	`890,125`
Other Convertible notes issued since July 2016	`36,250`	`36,250`
Premiums – Convertible notes issued since July 2016	`1,345,928`	`1,420,928`
Total – Convertible notes payable, net	`$3,453,518`	`$3,704,403`

Legacy Notes Issued Prior to July 2016 – September 2013 to July 2016

On September 27, 2013, the Company issued a convertible note to an unrelated party for $250,000 that matured on September 27, 2015. The note bears an interest rate of 10% per annum with a floor of $.005 per share, and principal is convertible in part or in whole into shares of the Company's common stock using the average closing prices for five trading days directly preceding the conversion date. Interest is not convertible and is due upon conversion or at maturity date. Evolution Capital Partners, LLC, acquired the note through an assignment in December 2015. The unconverted balance at April 30, 2021, was $250,000.

On October 18, 2013, the Company issued a convertible note to an unrelated party for $125,000 that matured on October 18, 2015. The note bears an interest rate of 10% per annum with a floor of $.005 per share, and principal is convertible in part or in whole into shares of the Company's common stock using the average closing prices for five trading days directly preceding the conversion date. Interest is not convertible and is due upon conversion or at the maturity date. Evolution Capital Partners, LLC, acquired the note through an assignment in December 2015. The unconverted balance at April 30,2021, was $68,850.

On November 22, 2013, the Company issued a convertible note to an unrelated party for $150,000 that matured on November 22, 2015. The note bears an interest rate of 10% per annum with a floor of $.005 per share, and principal is convertible in part or in whole into shares of the Company's common stock using the average closing prices for five trading days directly preceding the conversion date. Interest is not convertible and is due upon conversion or at the maturity date. Evolution Capital Partners, LLC, acquired the note through an assignment in December 2015. The unconverted balance at April 30,2021, was $150,000.

On December 2, 2014, the Company entered into a collateralized secured convertible promissory note with LG Capital Funding, LLC ("LG"), a New York limited liability company, for an 8% convertible promissory note with an aggregate principal amount of $73,500, which together with any unpaid accrued interest was due on December 2, 2015. This convertible note together with any unpaid accrued interest is convertible into shares of common stock at the holder's option at a variable conversion price calculated as 58% of the average of the lowest three closing bid prices during the ten-trading day period ending on the conversion date. This note was funded on December 10, 2014, when the Company received cash in the amount of $70,000, with the remaining $3,500 being used for LG’s legal and other origination expenses. The unconverted balance of the note at April 30,2021, of $67,141 and accrued interest of $79,193 was

written off and included in gain on extinguishment of debt.

NUTRANOMICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

April 30, 2021 (Unaudited)

On December 2, 2014, the Company entered into a convertible promissory note with JMJ Financial, a Nevada sole proprietorship (“JMJ”), with a face amount of $350,000, of which the Company is to assume $35,000 in original interest discount (“OID”), which together with any unpaid accrued interest was due on Dec 2, 2016. The note is to be funded by JMJ at its discretion, and the initial tranche was funded on December 16, 2014, when the Company received cash in the amount of $55,000. The note balance funded (plus a pro rata portion of the OID) together with any unpaid accrued interest is convertible into shares of common stock at a variable conversion price calculated as 65% of the average of the lowest trade price during a 25-day period ending on the last complete trading day prior to the conversion date. On December 16, 2014, the Company estimated the fair market value of the derivative liability associated with the bifurcated conversion feature to be $71,321. The unconverted balance of the note at April 30,2021, of $33,744 and accrued interest of $40,312 was written off and included in gain on extinguishment of debt.

On June 2, 2015, the Company entered into a convertible promissory note with Firehole River Capital, LLC for a 12% convertible promissory note with an aggregate principal amount of $27,500 which together with any unpaid accrued interest was due on March 2, 2015. This convertible note together with any unpaid accrued interest is convertible into shares of common stock at the holder's option at a variable conversion price calculated as 58% of the Market Price, which means the lowest Trading Price (defined as the closing bid prices) during the 10-trading day period ending on the last complete trading day prior to the conversion date. On July 8, 2015 the Company received cash in the amount of $17,400, with the remaining $10,100 being used for legal fees. The Company analyzed the note on the issuance date and determined that the variable conversion price exceeded the authorized number of shares resulting in the need for bifurcation into a separate derivative liability valued at fair market value. The Company estimated the fair market value of the derivative liability associated with the bifurcated conversion feature to be $31,695. The unconverted principal balance of the note at April 30,2021, was $22,483.

On September 14, 2015, at the time of former CEO, Mr. Doron’s, resignation, Mr. Doron received a convertible note from the Company in the aggregate principal amount of $299,382 in satisfaction of his accrued salary and stock payables. This note matured on March 14, 2016 and bears no interest. This convertible note is convertible into shares of common stock at the holder's option at 100% of the closing bid price of such common stock on the trading day immediately preceding the conversion. The Company determined that the variable conversion price exceeded the authorized number of shares resulting in the need for bifurcation into a separate derivative liability valued at fair market value. On October 31, 2015, the Company estimated the fair market value of the derivative liability associated with the bifurcated conversion feature to be $4,291 and a discount on the note of $4,291. On March 23, 2018, Mr. Doron sold $25,000 of face value of the note to a third party. During the year ended July 31, 2019 Mr. Doron sold an additional $105,000 of face value of the note to a third party (a settlement arrangement). During the year ended July 31, 2020, Mr. Doron sold an additional $35,000 of the face value of the note to a third party. The remaining unconverted balance of the note at April 30,2021, was $134,382.

Notes Issued During Restructuring Period – July 2016 to Present

On October 24, 2017, the Company issued a convertible note payable for $50,000 to Livingston Asset Management LLC for certain services to be rendered in conjunction with financial and operational restructuring. The note has an interest rate of 10% and matured on April 30, 2018. The note is subject to customary default provisions for similar notes. The note may be converted into common stock at any time after issuance at a 25% discount to the lowest closing bid price for the stock during the 30 trading days immediately preceding the delivery of conversion notice to the Company. The convertible note was accounted for as stock settled debt under ASC 480 and recorded a premium of $33,333 charged to interest expense. The note is now covered by the 3(a)(10) settlement.

On February 14, 2018 the Company issued a convertible note payable to Oscaleta Partners, LLC in the amount of $1,200. The note funded expenses incurred by the Company during restructuring. The note has debt discount of $200 to be amortized to interest expense over the life of the note. The note has an interest rate of 12%, matured on August 31, 2018 and can be converted into common shares at the lesser of: i) 75% of the price of the common stock at the date the note was issued, or ii) 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. Due to the variable conversion pricing feature the note is considered to include a derivative for which a fair market value was calculated. A derivative liability of $1,200 was recorded with a charge to debt discount, which was amortized to interest expense as of July 31, 2019. The note balance as of April 30,2021, is $1,200.

On March 23, 2018, the Company issued a convertible note payable to an individual investor in the amount of $20,000; the funds from the note were used for general corporate purposes. The note has an interest rate of 12%, matured on March 19, 2019 and can be converted into common shares at the lesser of: i) 75% of the price of the common stock at the date the note was issued, or ii) 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. Due to the variable conversion pricing feature the note is considered to include a derivative for which a fair market value was calculated. A derivative liability of $27,936 was recorded with charges to derivative expense of $7,936 and to debt discount of $20,000, which was fully amortized to interest expense as of April 30,2021. The note balance as of April 30, 2020, is $20,000.

NUTRANOMICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

April 30, 2021 (Unaudited)

On May 1, 2018 the Company issued a convertible note payable for financial services to Oscaleta Partners, LLC in the amount of $25,000. The note has an interest rate of 10%, matured on December 31, 2018 and can be converted into common shares at the 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. The convertible note was accounted for as stock settled debt under ASC 480 and recorded a premium of $25,000 with a charge to interest expense at issuance. The note and accrued interest were converted into 133,917,280 shares of the Company’s common stock on April 28, 2021.

On June 1, 2018 the Company issued a convertible note payable for financial services to Oscaleta Partners, LLC in the amount of $25,000. The note has an interest rate of 10%, matured on July 31, 2019 and can be converted into common shares at 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. The convertible note was accounted for as stock settled debt under ASC 480 and recorded a premium of $25,000 with a charge to interest expense at issuance. The note and accrued interest were converted into 133,067,960 shares of the Company’s common stock on April 28, 2021.

On June 29, 2018 the Company issued a convertible note payable to Oscaleta Partners, LLC in the amount of $2,500. The note funded expenses incurred by the Company during restructuring. The note has debt discount of $135 to be amortized to interest expense over the life of the note. The note has an interest rate of 12%, matured on December 29, 2018 and can be converted into common shares at the lesser of: i) 75% of the price of the common stock at the date the note was issued, or ii) 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. Due to the variable conversion pricing feature the note is considered to include a derivative for which a fair market value was calculated. A derivative liability of $3,176 was recorded with a charge to debt discount of $2,500 to be amortized over the life of the note and a charge of $976 to derivative expense. The note balance as of April 30,2021, is $2,500.

On July 1, 2018 the Company issued a convertible note payable for financial services to Oscaleta Partners, LLC in the amount of $25,000. The note has an interest rate of 10%, matured on February 28, 2019 and can be converted into common shares at 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. The convertible note was accounted for as stock settled debt under ASC 480 and recorded a premium of $25,000 with a charge to interest expense at issuance. The note and accrued interest were converted into 132,246,040 shares of the Company’s common stock on April 28, 2021.

On July 20, 2018 the Company issued a convertible note payable to Oscaleta Partners, LLC in the amount of $3,500. The note has debt discount of $12. The note has an interest rate of 12%, matured on January 21, 2019 and can be converted into common shares at the lesser of: i) 75% of the price of the common stock at the date the note was issued, or ii) 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. Due to the variable conversion pricing feature the note is considered to include a derivative for which a fair market value was calculated. A derivative liability of $4,688 was recorded with a charge to debit discount of $3,500 to be amortized over the life of the note and a charge of $1,188 to derivative expense. The note balance as of April 30,2021, is $3,500.

On August 1, 2018 the Company issued a convertible note payable for financial services to Oscaleta Partners, LLC in the amount of $25,000. The note has an interest rate of 10%, matured on March 31, 2019 and can be converted into common shares at 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. The convertible note was accounted for as stock settled debt under ASC 480 and recorded a premium of $25,000 with a charge to interest expense at issuance. The note balance as of April 30,2021, is $25,000.

On August 15, 2018 the Company issued a convertible note payable to Oscaleta Partners, LLC in the amount of $7,500. The note has debt discount of $500. The note proceeds were paid directly to vendors for services rendered. The note has an interest rate of 12%, matured on February 14, 2019 and can be converted into common shares at the lesser of: i) 75% of the price of the common stock at the date the note was issued, or ii) 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. Due to the variable conversion pricing feature the note is considered to include a derivative for which a fair market value was calculated. A derivative liability of $12,018 was recorded with a charge to debt discount of $7,500 to be amortized over the life of the note and a charge of $4,518 to derivative expense. The note balance as of April 30,2021, is $7,500.

On September 1, 2018 the Company issued a convertible note payable for financial services to Oscaleta Partners, LLC in the amount of $25,000. The note has an interest rate of 10%, matured on April 30, 2019 and can be converted into common shares at 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. The convertible note was accounted for as stock settled debt under ASC 480 and recorded a premium of $25,000 with a charge to interest expense at issuance. The note balance as of April 30,2021, is $25,000.

NUTRANOMICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

April 30, 2021 (Unaudited)

On September 5, 2018 the Company issued a convertible note payable to Oscaleta Partners, LLC in the amount of $5,500. The note has debt discount of $319. The note proceeds were paid directly to vendors for services rendered. The note has an interest rate of 12%, matured on March 4, 2019 and can be converted into common shares at the lesser of: i) 75% of the price of the common stock at the date the note was issued, or ii) 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. Due to the variable conversion pricing feature the note is considered to include a derivative for which a fair market value was calculated. A derivative liability of $8,060 was recorded with a charge to debt discount of $5,500 to be amortized over the life of the note and a charge of 2,560 to derivative expense. The note balance as of April 30,2021, is $5,500.

On September 17, 2018 the Company issued a convertible note payable to Oscaleta Partners, LLC in the amount of $3,500. The note has debt discount of $500. The note proceeds were used for general corporate purposes. The note has an interest rate of 12%, matured on March 16, 2019 and can be converted into common shares at the lesser of: i) 75% of the price of the common stock at the date the note was issued, or ii) 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. Due to the variable conversion pricing feature the note is considered to include a derivative for which a fair market value was calculated. A derivative liability of $5,244 was recorded with a charge to debt discount of $3,500 to be amortized over the life of the note and a charge of 1,744 to derivative expense. The note balance as of April 30,2021, is $3,500.

On October 1, 2018 the Company issued a convertible note payable for financial services to Oscaleta Partners, LLC in the amount of $25,000. The note has an interest rate of 10%, matured on May 31, 2019 and can be converted into common shares at 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. The convertible note was accounted for as stock settled debt under ASC 480 and recorded a premium of $25,000 with a charge to interest expense at issuance. The note balance as of April 30,2021, is $25,000.

On October 5, 2018 the Company issued a convertible note payable to Oscaleta Partners, LLC in the amount of $4,000. The note has an interest rate of 12%, matured on March 16, 2019 and can be converted into common shares at the lesser of: i) 75% of the price of the common stock at the date the note was issued, or ii) 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. Due to the variable conversion pricing feature the note is considered to include a derivative for which a fair market value was calculated. A derivative liability of $5,244 was recorded with a charge to debt discount of $4,000 to be amortized over the life of the note and a charge of 1,244 to derivative expense. The note balance as of April 30,2021, is $4,000.

On November 1, 2018 the Company issued a convertible note payable for financial services to Oscaleta Partners, LLC in the amount of $25,000. The note has an interest rate of 10%, matured on June 30, 2019 and can be converted into common shares at 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. The convertible note was accounted for as stock settled debt under ASC 480 and recorded a premium of $25,000 with a charge to interest expense at issuance. The note balance as of April 30,2021, is $25,000.

On November 16, 2018 the Company issued a convertible note payable to Oscaleta Partners, LLC in the amount of $4,000. The note has debt discount of $500. The note proceeds were paid directly to vendors for services rendered. The note has an interest rate of 12%, matured on May 15, 2019 and can be converted into common shares at the lesser of: i) 75% of the price of the common stock at the date the note was issued, or ii) 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. Due to the variable conversion pricing feature the note is considered to include a derivative for which a fair market value was calculated. A derivative liability of $5,244 was recorded with a charge to debt discount of $3,500 to be amortized over the life of the note and a charge of 1,744 to derivative expense. The note balance as of April 30,2021, is $4,000.

On December 1, 2018 the Company issued a convertible note payable for financial services to Oscaleta Partners, LLC in the amount of $25,000. The note has an interest rate of 10%, matures on July 31, 2019 and can be converted into common shares at 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. The convertible note was accounted for as stock settled debt under ASC 480 and recorded a premium of $25,000 with a charge to interest expense at issuance. The note balance as of April 30,2021, is $25,000.

On January 1, 2019 the Company issued a convertible note payable for financial services to Oscaleta Partners, LLC in the amount of $25,000. The note has an interest rate of 10%, matures on August 31, 2019 and can be converted into common shares at 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. The convertible note was accounted for as stock settled debt under ASC 480 and recorded a premium of $25,000 with a charge to interest expense at issuance. The note balance as of April 30,2021, is $25,000.

NUTRANOMICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

April 30, 2021 (Unaudited)

On February 1, 2019, the Company issued a convertible note payable for financial services to Oscaleta Partners, LLC in the amount of $25,000. The note has an interest rate of 10%, matures on September 30, 2019 and can be converted into common shares at 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. The convertible note is accounted for as stock settled debt under ASC 480 and a premium of $25,000 was charged to interest expense on the issuance date. The note balance as of April 30,2021, is $25,000.

On February 2, 2019, the Company issued a convertible note payable to an individual investor in the amount of $30,000. The note has an interest rate of 12%, matures on February 2, 2019 and can be converted into common shares at the lesser of: i) 75% of the price of the common stock at the date the note was issued, or ii) 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. Due to the variable conversion pricing feature the note is considered to include a derivative for which a fair market value was calculated and recorded. The note balance as of April 30,2021, is $25,000.

On March 1, 2019, the Company issued a convertible note payable for financial services to Oscaleta Partners, LLC in the amount of $25,000. The note has an interest rate of 10%, matures on October 31, 2019 and can be converted into common shares at 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. The convertible note will be accounted for as stock settled debt under ASC 480 and a premium of $25,000 will be charged to interest expense on the issuance date. The note balance as of April 30,2021, is $25,000.

On April 1, 2019, the Company issued a convertible note payable for financial services to Oscaleta Partners, LLC in the amount of $25,000. The note has an interest rate of 10%, matures on November 30, 2019 and can be converted into common shares at 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. The convertible note is accounted for as stock settled debt under ASC 480 and a premium of $25,000 will be charged to interest expense on the issuance date. The note balance as of April 30,2021, is $25,000.

On April 4, 2019, the Company issued a convertible note payable for cash payments of $24,500 with an original issue discount of $2,500 to Oscaleta Partners, LLC in the amount of $27,000. The OID will be amortized over the life of the loan. The note has an interest rate of 12%, matures on October 3, 2019 and can be converted into common shares at the lesser of: $.00075 or 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. Due to the variable conversion pricing feature the note is considered to include a derivative for which a fair market value was calculated and recorded. The note balance as of April 30,2021, is $27,000.

On May 1, 2019, the Company issued a convertible note payable for financial services to Oscaleta Partners, LLC in the amount of $25,000. The note has an interest rate of 10%, matures on December 31, 2019 and can be converted into common shares at 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. The convertible note is accounted for as stock settled debt under ASC 480 and a premium of $25,000 was charged to interest expense on the issuance date. The note balance as of April 30,2021, is $25,000.

On June 1, 2019, the Company issued a convertible note payable for financial services to Oscaleta Partners, LLC in the amount of $25,000. The note has an interest rate of 10%, matures on January 31, 2020 and can be converted into common shares at 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. The convertible note is accounted for as stock settled debt under ASC 480 and a premium of $25,000 was charged to interest expense on the issuance date. The note balance as of April 30,2021, is $25,000.

On June 7, 2019, the Company issued a convertible note payable to an individual investor in the amount of $20,000. The note has an interest rate of 12%, matures on June 6, 2020 and can be converted into common shares 40% of the lowest bid price during the 20 trading days immediately preceding the date of the conversion notice. The convertible note is accounted for as stock settled debt under ASC 480 and a premium of $30,000 was charged to interest expense on the issuance date. The note balance as of April 30,2021, is $20,000.

On July 1, 2019, the Company issued a convertible note payable for financial services to Oscaleta Partners, LLC in the amount of $25,000. The note has an interest rate of 10%, matures on February 28, 2020 and can be converted into common shares at 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. The convertible note will be accounted for as stock settled debt under ASC 480 and a premium of $25,000 was charged to interest expense on the issuance date. The note balance as of April 30,2021, is $25,000.

NUTRANOMICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

April 30, 2021 (Unaudited)

On July 11, 2019, Trillium Partners LP purchased $20,000 of the note first issued to the former CEO Michael Doron on September 14, 2015. Following the sale, the original note balance was reduced to $169,382. The assignment and restatement of terms provides for conversion of the principal into common shares at the lower of $.001 or 50% of the lowest closing bid price during the 30 trading days immediately preceding the issuance of a conversion notice. Due to the variable conversion pricing feature the note is considered to include a derivative for which a fair market value of $80,016, was calculated and recorded. The original Doron note balance is $169,382 following the assignment. On September 27, 2019, Trillium converted $9,500 of principal into 70,666,667 common shares, on January 16, 2020, Trillium converted $1,700 of principal into 56,000,000, common shares and on February 18, 2020 an additional $7,000 in principal was converted into common shares. Following the conversions, the note balance as of April 30,2021, is $1,800. $45,609 of the derivative liability was reclassified to additional paid in capital in conjunction with the conversions.

On July 15, 2019, the Company issued a convertible note payable to an individual investor in the amount of $15,000. The note has an interest rate of 12%, matures on July 14, 2020 and can be converted into common shares at 40% of the lowest bid price during the 20 trading days immediately preceding the date of the conversion notice. The convertible note is accounted for as stock settled debt under ASC 480 and a premium of $22,500 was charged to interest expense on the issuance date. The note balance as of April 30,2021, is $15,000.

On August 1, 2019, the Company issued a convertible note payable for financial services to Oscaleta Partners, LLC in the amount of $25,000. The note has an interest rate of 10%, matures on February 28, 2020 and can be converted into common shares at 50% of the lowest bid price during the 30 trading days immediately preceding the date of the conversion notice. The convertible note will be accounted for as stock settled debt under ASC 480 and a premium of $25,000 will be charged to interest expense on the issuance date. The note balance as of April 30,2021, is $25,000.

On February 7, 2020, the Company issued a convertible note to an individual in the amount of $20,000. The note bears interest at 10% per annum, matures on February 7, 2021 and is convertible into common stock. The conversion price is to be 40% of the lowest closing bid price during the twenty days preceding the conversion notice. Due to the fixed percentage conversion terms it will be treated as stock settled debt in accordance with ASC 480.

Court Approved Settlement under Rule 3(a)(10)

On December 18, 2015, accounts payable totaling $45,000 were converted into convertible notes in exchange for a 10% one-time fee. Two $5,000 notes are past due at January 31, 2016 and are convertible at a 10% discount to the prior day’s closing price. The balance ($35,000) of the notes were due July on 18, 2016 and are convertible at a 42% discount to the average of the ten prior trading days’ closing price. $35,000 of derivative liability was recorded as debt discount upon issuance of the note maturing on July 18, 2016. The note is now covered by the 3(a)(10) settlement and reclassified to the 3(a)(10) note along with the related derivative liability being reclassified as put premium. (See Note 7)

Six past due convertible fee notes totaling $150,000 issued to Oscaleta Partners LLC for each month from November 1, 2017, to April 1, 2018, were covered in the 3(a)(10) settlement. The convertible notes were accounted for as stock settled debt under ASC 480 and premiums of $150,000 were recorded with a charge to interest expense at issuance. The notes have been reclassified to the 3(a)(10), liability. (See Note 7)

Other Convertible Notes

On October 15, 2018 an individual investor was issued a convertible note payable in the amount of $10,000. The note proceeds were used for general corporate purposes. The note has an interest rate of 10%, matures on October 15, 2020 and can be converted into common shares at fixed price of $.0004. The note balance as of April 30,2021, is $10,000.

NUTRANOMICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

April 30, 2021 (Unaudited)

On May 16, 2019, the Company issued a note to an individual for $25,000; cash used for general corporate purposes. The note calls for monthly principal repayments of $5,000, beginning July 1, 2019. The payments due have not been made and penalties of $2,500, will be charged after each 45-day delinquent payment, the payment is to be additional common shares valued at the market price on the 46^th day of delinquency. Additionally, a royalty payment of 10% of specific product sales capped at approximately $3,000 is charged in lieu of interest. The note balance as of April 30,2021, is $25,000. The Company and the note holder have reached an oral agreement to settle the liability and will execute the final agreement prior to the end of the fiscal year (July 31, 2021).

The May 16, 2019 note includes a warrant for $10,000 in common stock at the market price on the date of issuance. The price of the Company’s stock was $.0009 on the note issuance date, which equates to 11,111,111 common shares, resulting in $10,000 recorded as additional paid in capital offset with derivative liability. Changes to the value of the warrant, if material will be recorded as fair market values changes to the derivative liability at each reporting date. The terms of the note have been amended and will be finalized by July 31, 2021.

NOTE 7 – DEBT SETTLEMENT UNDER COURT ORDER – 3(a)(10)

On January 3, 2019, a US District Court approved a settlement that covered $950,769 of notes, convertible notes and amounts owed to various creditors (collectively the “Creditors”)”). One Creditor withdrew from the settlement leaving $890,125 in the final settlement pool. Livingston Asset Management, LLC, (“LAM”) under individual agreements with the Creditors, fixed the amount owed and as such there is no further interest due on these liabilities. As a result of the change in obligor amounts formerly classified as notes payable, convertible notes, accrued expenses and accounts payable have been reclassified into the 3(a)(10) settlement. The terms of the agreements (including the related agreement between LAM and the Company) the Company will issue shares directly to LAM as requested and LAM will sell the shares (unrestricted as allowed under Section 3(a)(10) of the 1933 Securities Act) on the open market through unaffiliated brokers. The shares are issued to LAM at a 50% discount to the sale price, as such the Company has accounted for the $890,125 settlement amount as stock settled debt under ASC 480 and recorded a premium of $890,125 with a charge to loss on debt extinguishment of $673,699. The charge to loss on debt extinguishment was net of premiums and derivative liabilities directly associated with the Creditor liabilities as originally recorded. Sales to liquidate creditor balances have occurred as of October 31, 2020, however the accounting for the payments and costs have been delayed due to personnel restrictions during the COVID 19 quarantine, and the balance remains $890,125. (See Note 10)

NOTE 8- DERIVATIVE LIABILITIES

FASB ASC 820 defines fair value, establishes a framework for measuring fair value under U.S. generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under FASB ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, with the first two inputs considered observable and the last input considered unobservable, that may be used to measure fair value as follows:

Level one — Quoted market prices in active markets for identical assets or liabilities;

Level two – Inputs, other than level one inputs, that are either directly or indirectly observable; and

Level three — Unobservable inputs developed using estimates and assumptions, which are developed

by the reporting entity and reflect those assumptions that a market participant would use.

Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter and has determined that all derivative liabilities are level three. The Company has one liability measured at fair value on a recurring basis, which consists of a derivative liability on certain convertible notes payable and warrants. As of April 30,2021, this derivative liability had an estimated fair value of $568,060. The Company has no assets that are measured at fair value on a recurring basis.

NUTRANOMICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

April 30, 2021 (Unaudited)

The following table presents information about our derivative liability related to convertible notes, which was our only financial instrument measured at fair value on a recurring basis using significant inputs other than level one inputs that are either directly or indirectly observable (Level 2) as of April 30, 2021:

	Total
Balance at July 31, 2020	`538,059`
Initial derivative expense	`30,001`

Balance at April 30, 2021	`$568,060`

The fair value of this derivative liability was calculated using the multinomial lattice models that values the derivative liability within the notes based on a probability weighted discounted cash flow model. These models are based on future projections of the various potential outcomes. The features in the notes that were analyzed and incorporated into the model included the conversion feature with the reset provisions; redemption provisions; and the default provisions. Assumptions used to calculate the fair value of the derivative liability were as follows:

Expected term in years	0-1
Risk-free interest rates	1.7%
Volatility	235%
Dividend yield	0%

In addition to the assumptions above, the Company also takes into consideration whether or not the Company would participate in another round of financing and if that financing is registered or not and what that stock price would be for the financing at that time.

Derivative liabilities for notes that have matured remain at the historic liability amount unless converted into common shares at which time the proportionate principal and derivative liability are decreased. All of the Company’s convertible notes having embedded conversion features treated as derivative liabilities have matured and therefore no changes due to fair market valuation have been calculated during the nine months ended April 30, 2021.

NOTE 9 – SETTLEMENT RESERVES

Certain liabilities and contingencies have been accrued as expense and are collectively classified as settlement reserves. The balance at April 30, 2021 of $1,110,241 includes judgement amounts for a former note holder and $550,874, due to a hemp venture partner, which has been reclassified to settlement reserves due to the uncertainty surrounding the ability to procure the hemp for which the funds were advanced. During the nine months ended April 30, 2021, management has concluded that legal settlement reserves were more than the expected liabilities and recognized $382,308 of other income related to the adjustment of reserves.

NOTE 10- STOCKHOLDERS’ DEFICT

There are 25,000,000 shares of Series A Preferred stock authorized and 1,000,000 outstanding at April 30, 2021.

On March 17, 2020, the Wyoming Secretary of State approved the Company’s increase of authorized common stock to 10,000,000,000.

The Company has ten billion authorized shares. At April 30, 2021, and July 31, 2020, there are 4,163,335,831 and 4,117,033,449 shares of common stock, outstanding, respectively.

The stockholders’ deficit is $6,559,758, at April 30, 2021 and $7,058,112 at July 31, 2020.

Common Stock Outstanding under 3(a)(10) Settlement

The total shares issued for the 3(a)(10) as of April 30,2021 is 1,256,288,000. The shares are issued at par with equal offset to additional paid in capital until proceeds of share sales are confirmed by the creditor covered under the settlement, at which time the liability will be reduced with a credit to additional paid in capital. As of April 30, 2021, no such confirmations have been received.

NUTRANOMICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

April 30, 2021 (Unaudited)

Issuance of Common Stock for Conversion of Notes Payable

On April 28, 2021, the Company issued 399,231,280 shares of common stock to Oscaleta Partners LLC in conversion of $75,000, $21,418 and $3,390 of principal, accrued interest and conversion fees respectively.

NOTE 11- SUBSEQUENT EVENTS

On May 21, 2021, the Company issued 73.000,000 shares of common stock to Trillium Partners LP in conversion of $26,800 and $2,400 of principal and conversion fees respectively. The original note was dated September 14, 2015 and was issued for officer compensation, Trillium obtained the notes for cash in a purchase and assignment.

Between May 1, and May 27, 2021, the Company issued 496,451,514 shares of common stock to Oscaleta Partners LLC in conversion of $150,000, $38,273 and $6,780 of principal, accrued interest and conversion fees respectively. The notes were dated from May 1, 2018 through January 1, 2019 for services and fees.

Between May 21, and May 27, 2021, the Company issued 298.405,334 shares of common stock to Oscaleta Partners LLC in conversion of $58,700, $18,764 and $10,240 of principal and conversion fees respectively. The notes were dated between February 12, 2018 and April 4, 2019 and were issued for cash,

Issuance of Convertible Note Payable

On May 3, 2021, The Company issued a convertible note payable to Livingston Asset Management LLC, for $45,000 in principal of which $5,000 is original issue discount (“OID”) and $40,000 cash to be used for general corporate purposes. The note matures October 31, 2021, bears interest of 10% and is convertible into common stock at a fixed price of $0.0002 per share.

Management has reviewed all events and contingencies since April 30,2021 through the issuance date of the report and found not material events or contingencies of a reportable nature.

NutraNomics, Inc.
By:	*/s/ Jonathan Bishop*
Jonathan Bishop
Principal Executive Officer and Director

2020		98-0603540
(Primary Standard Industrial Classification Code Number)		(I.R.S. Employer Identification Number)

	Price to Public	Commissions (1)	Proceeds to Company (2)	Proceeds to Other Persons (3)
Per Share	`$0.00026`	`$0`	`$0.00026`	None
Minimum Investment	`$250.00`	`$0`	`$250.00`	None
Maximum Offering	`$13,000,000`	`$0`	`$13,000,000`	None

	Page

OFFERING SUMMARY, PERKS AND RISK FACTORS	7
OFFERING SUMMARY	7
The Offering	7
Investment Analysis	8
RISK FACTORS	8
DILUTION	17
USE OF PROCEEDS TO ISSUER	19
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	20
Results of Operations	23
Liquidity and Capital Resources	23
Off-Balance Sheet Arrangements	24
Critical Accounting Policies	25
DIRECTORS, EXECUTIVE OFFICERS AND SIGNIFICANT EMPLOYEES	25
COMPENSATION OF DIRECTORS AND EXECUTIVE OFFICERS	26
SECURITY OWNERSHIP OF MANAGEMENT AND CERTAIN SECURITYHOLDERS	27
SECURITIES BEING OFFERED	27
DISQUALIFYING EVENTS DISCLOSURE	29
ERISA CONSIDERATIONS	29
INVESTOR ELIGIBILITY STANDARDS	31
PART III: EXHIBITS	32
SIGNATURES	33
ACKNOWLEDGMENT ADOPTING TYPED SIGNATURES	33
SECTION F/S FINANCIAL STATEMENTS	34

Type of Stock Offering:	Common Stock

Price Per Share:	$0.00026

Minimum Investment:	$250.00 per investor (961,538 Shares of Common Stock at Maximum Offering Price)

Maximum Offering:	$13,000,000. The Company will not accept investments greater than the Maximum Offering amount.

Maximum Shares Offered:	50,000,000,000 Shares of Common Stock

Use of Proceeds:	See the description in section entitled "USE OF PROCEEDS TO ISSUER" on page 18 herein.

Voting Rights:	The Shares have full voting rights.

Length of Offering:	Shares will be offered on a continuous basis until either (1) the maximum number of Shares or sold; (2) 365 days from the date of qualification by the Commission, (3) the Company in its sole discretion withdraws this Offering.

Common Stock Outstanding prior to this Offering (1)	5,851,316,410 Shares
Common Stock in this Offering	50,000,000,000 Shares
Stock to be outstanding after the offering (2)	55,851,316,410 Shares

Percentage of shares offered that are sold	100%

Price to the public charged for each share in this Offering	`$0.00026`

Historical net tangible book value per share (1)	`$(0.0011)`

Increase in net tangible book value per share attributable to new investors in this Offering (2)	`$0.0014`

Net tangible book value per share, after this Offering	$ 0.0002

Dilution per share to new investors	`$0.0002`

Assuming $0.00026 Offering Price:	10%	25%	50%	75%	100%
Working Capital	$1,000,000	$2,950,000	$6,200,000	$9,450,000	$12,700,000

Repayment of Outstanding Debts	$300,000	$300,000	$300,000	$300,000	$300,000

Total	$1,300,000	$3,250,000	$6,500,000	$9,750,000	$13,000,000

Name and Position	Shares Beneficially Owned Prior to Offering	Shares Beneficially Owned After Offering

Jonathan Bishop, CEO, CFO, Treasurer, Secretary, & Director¹	1,000,000 Preferred Series A Shares	1,000,000 Preferred Series A Shares

Description	Item	Exhibit
Articles of Incorporation filed with the State of Nevada on March 15, 2007^²	Item 17.2	1A-2A1
Amendment to Articles of Incorporation filed with the State of Nevada on October 6, 2015^³	Item 17.2	1A-2A2
Amendment to Articles of Incorporation filed with the State of Nevada on October 6, 2015.ⁱⁱ	Item 17.2	1A-2A3
Amendment to Articles of Incorporation filed with the State of Nevada on December 11, 2015.ⁱⁱ	Item 17.2	1A-2A4
Amendment to Articles of Incorporation filed with the State of Wyoming on September 9, 2019.*	Item 17.2	1A-2A5
Amendment to Articles of Incorporation filed with the State of Wyoming on March 17, 2020.*	Item 17.2	1A-2A6
Amendment to Articles of Incorporation filed with the State of Wyoming on August 13, 2021 .*	Item 17.2	1A-2A7
Amendment to Articles of Incorporation filed with the State of Wyoming on September 14, 2021. *	Item 17.2	1A-2A8
Bylaws of the Companyⁱ	Item 17.2	1A-2B
Subscription Agreement	Item 17.4	1A-4
Profit Participation Agreement with AK Investments dated September 20, 2019*	Item 17.6	1A-6A1
Convertible Note issued to Trillium Partners LP, dated July 11, 2019*	Item 17.6	1A-6A2
Convertible Note issued to Michael Doron, dated July 15, 2019*	Item 17.6	1A-6A3
Convertible Note issued to Oscaleta Partners LLC, dated August 1, 2019*	Item 17.6	1A-6A4
Convertible Note issued to Trillium Partners LP, dated February 7, 2020*	Item 17.6	1A-6A5
Convertible Note issued to Michael Doron, dated February 7, 2020*	Item 17.6	1A-6A6
Legal Opinion and Consent of JDT Legal, PLLC*	Item 17.12	1A-12

	Page
April 30, 2021 Financial Statements:

Condensed Balance Sheets at April 30, 2021 and July 31, 2020	35

Condensed Statements of Operations for the three and nine months ended April 30, 2021 and 2020	36

Condensed Statements of Stockholders' Deficit for the three and nine months ended April 30,2021 and January 31, 2020	37

Condensed Statements of Cash Flows for the three and nine months ended April 30, 2021 and 2020	39

Notes to Condensed Financial Statements	40

July 31, 2020 Financial Statements:

Balance Sheets at July 31, 2020 and 2019	53

Statements of Operations for the years ended July 31, 2020 and 2019	54

Statements of Stockholders' Deficit for the years ended July 31, 2020 and 2019	55

Statements of Cash Flows for the years ended July 31, 2020 and 2019	56

Notes to Financial Statements	57

	For the Twelve Months Ended July 31,
	2020	2019

REVENUES	`$871`	`$59,544`
COST OF SALES	`1,278`	`37,979`

GROSS PROFIT	`(407)`	`21,565`

OPERATING EXPENSES
General and administrative	`326,267`	`79,412`
Advertising and marketing	`15,439`	`9,626`
Professional fees	`83,108`	`434,583`
Salaries and wages	`170,288`	`71,557`
Total Operating Expenses	`595,102`	`595,178`

OPERATING (LOSS)	`(595,509)`	`(573,613)`

OTHER INCOME (EXPENSE)
Other income(expense)	`-`	`(22,010)`
Change in fair value of derivative	`-`	`(98,789)`
Derivative expense	`(60,140)`	`(191,580)`
Interest expense	`(295,146)`	`(678,761)`
Loss on extinguishment	`-`	`(673,699)`
Total Other Income (Expense)	`(355,286)`	`(1,664,839)`

NET (LOSS) BEFORE INCOME TAXES	`(950,795)`	`(2,238,452)`

Provision for income taxes	`-`	`-`

NET (LOSS)	`$(950,795)`	`$(2,238,452)`

BASIC AND DILUTED LOSS PER SHARE	`$(0.0003)`	`$(0.0016)`

Weighted Average Shares Outstanding - Basic and Diluted	`3,725,474,097`	`1,390,624,924`

NUTRANOMICS, INC.
STATEMENTS OF CASH FLOWS For the Years ended July 31, 2020 and 2019 (Unaudited)
	The Year Ended
	July 31,
	2020			2019
OPERATING ACTIVITIES
Net (Loss)	$	(950,795	)	$	(2,238,452	)
Adjustments to reconcile net (loss) to net cash used in operating activities:
Loss on debt extinguishment		-			673,699
Impairment charge for intangible asset		3,703			-
Stock based expense		3,300			-
Interest expense for note premium		38,333			490,000
Amortization of debt discount		9,494			63,652
Short-term notes issued for professional fees & expenses		25,000			300,000
Changes in fair market value of derivatives		-			98,789
Derivative expense		60,140			213,076
Changes in operating assets and liabilities:
Prepaid expenses		-			24,000
Other assets		-			23,267
Inventory		-			25,234
Deferred revenue		-			(222)
Accounts payable and accrued expenses		240,555			159,110
Net Cash (Used in) Operating Activities		(570,270	)		(167,847	)

FINANCING ACTIVITIES
Proceeds from profit share partner		550,874			-
Proceeds from convertible debt issued		20,000			167,977
Net Cash Provided by Financing Activities		570,874			167,977

Net Increase in Cash and Cash Equivalents		604			130

Cash and Cash Equivalents, Beginning of Year		739			609

Cash and Cash Equivalents, End of Year	$	1,343		$	739
Supplemental Disclosures of Cash Flow Information:
Cash paid during the period for:
Interest	$	-		$	-
Income taxes	$	-		$	-

Non-cash Investing and Financing activities:
Debt discount	$	-		$	28,946
Conversion of debt to common stock	$	252,786		$	-
Convertible debt premium	$	38,332		$	562,705
Derivative liability reclassified to settlement reserve (2020) and debt premium	$	4,444		$	54,608

	July 31, 2020	July 31, 2019
Accounts payable	$ 550,729	$ 527,229
Accrued interest	620,896	499,717
Other accrued expenses	177,819	84,513
Total	$ 1,349,444	$ 1,111,459

	Notes	Warrants	Total
Balance at July 31, 2018	`$445,790`	`$90,703`	`$536,493`
New warrants issued		`10,000`	`10,000`
Convertible notes issued, derivative expense	`191,580`		`191,580`
Convertible notes issued, debt discount	`97,115`		`97,115`
Conversions	`(149,252)`		`(149,252)`
Change in fair value of derivatives	`104,345`	`(5,556)`	`98,789`
Net reclassifications to premium on stock settled debt	`(18,507)`		`(18,507)`
Reclassification to settlement reserves	`(44,847)`	`(90,703)`	`(135,550)`
Balance at July 31, 2019	`626,224`	`4,444`	`630,668`
Reclassification of warrant related liability		`(4,444)`	`(4,444)`
Initial derivative expense	`60,140`	`-`	`60,140`
Extinguishment by conversion	`(148,305)`	`-`	`(148,305)`

Balance at July 31, 2020	`$538,059`	`$-`	`$538,059`

	2019	2018
Federal income taxes at 21%	`$(199,667)`	`$(470,075)`
State income tax, net of federal benefit	`-`	`-`
Change in net operating loss	`-`	`-`
Tax effect on non-deductible expenses and credits	`25,229`	`-`
Changes in valuation allowance	`174,438`	`470,075`
	`$-`	`$-`

	July 31,	July 31,
	2020	2019
Deferred tax asset attributable to:
Net operating loss carryover	`$9,133,338`	`$9,133,338`
Temporary differences	`654,345`	`594,345`
Less, valuation allowance	`(10,023,993)`	`(9,727,683)`
Net deferred tax asset	`$-`	`$-`

Deferred tax liability attributable to:
Depreciation	`$-`	`$-`
Net deferred tax liabilities	`$-`	`$-`